By 2028, Non-Vaccine mRNA Therapy Will Earn $2 Billion

Sales of mRNA non-vaccine therapies are anticipated to reach $2 billion by 2028, according to GlobalData, spurred by the clearance of prospective treatments.

Regulations And Directive Revisions For Human Medicines

New regulations should strengthen the expertise-driven evaluation and enable a more flexible centralised authorisation framework by supporting member states.

Vaccines Europe Undertakes Its First Regulatory Evaluation

To ensure adults are safe from diseases that can be prevented by vaccination, Vaccines Europe has outlined four critical tasks in its first pipeline assessment.

Top Biopharma Companies Show A Dip In Market Cap For Q3

GlobalData estimates that the average market capitalization of the top 20 biopharma companies tumbled from $3.45 trillion in Q2 to $3.14 trillion in Q3 2022.

New study finds promising treatment for cognitive deficits associated with cholestatic liver disease

Patients suffering from cholestatic liver disease may develop neurological symptoms like weariness and there is no treatment available for these conditions.